All In Biotech

Drug Trial Radar · NCT07616154

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Sep 2034

Study completion Sep 2035

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD. Primary Objective: \- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD. Secondary Objectives: * Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD. * Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD. * Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.

Conditions

  • Sickle Cell Disease

Interventions

  • Cyclophosphamide 50mgDrug

    IV

  • AbataceptDrug

    IV

  • AlemtuzumabDrug

    IV

  • HydroxyureaDrug

    IV

  • ThiotepaDrug

    IV

  • FilgrastimDrug

    IV

  • SirolimusDrug

    IV

  • AzathioprineDrug

    IV

  • TBIRadiation

    Radiaiton therapy

  • Hematopoietic Progenitor Cell InfusionProcedure

    Hematopoietic Progenitor Cell Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GVHD-free and rejection free survival (GRFS)Time frame: Up to 3 years after HCT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.